PTK6, sometimes known by its earlier name BRK, is a non-receptor tyrosine kinase, a type of signaling enzyme that sits inside the cell but relays messages from cell-surface receptors to the nucleus. Unlike many of its relatives, PTK6 is not normally active in most healthy adult epithelial tissues at high levels, yet it has been found overexpressed in a growing list of tumors, including breast, colon, prostate, and ovarian cancers. Because kinases can often be disabled with small-molecule drugs, they are among the most attractive targets in oncology. The problem, the researchers note, is that while PTK6 has been implicated in cancer progression broadly, its precise role in ovarian cancer and its value as a drug target had remained incompletely defined.

To close that gap, the team, led by Lan-Ting Zhou and Liangsheng Fan of The First Affiliated Hospital of Guangzhou Medical University together with colleagues at Xiangyang Central Hospital, began with a large-scale computational survey. They performed comprehensive multi-omics analyses to identify genes that are differentially expressed between ovarian tumors and healthy tissue, and then validated PTK6 expression across multiple independent datasets. The results were consistent: PTK6 was significantly upregulated in ovarian cancer compared with normal tissue. More importantly, when the researchers correlated PTK6 levels with clinical outcomes, high expression of the kinase was associated with poorer overall survival, poorer disease-specific survival, and poorer progression-free survival. In other words, patients whose tumors produced more PTK6 tended to fare worse, suggesting the enzyme is not merely a passenger but an active participant in the disease.

Single-cell transcriptomic analysis added an important layer of resolution to the picture. By examining gene expression in individual cells rather than in bulk tissue, the researchers could determine which cell types within a tumor actually produce PTK6. The answer was telling: PTK6 expression was predominantly localized to epithelial and malignant cell populations, the very cells that constitute the cancer itself. This specificity matters for drug development, because a target that is concentrated in malignant cells is more likely to yield a therapeutic window, harming the tumor while sparing healthy tissue.

With the association established, the team moved to direct functional tests. Using lentiviral-mediated short hairpin RNA, they knocked down PTK6 in ovarian cancer cell lines and measured what happened. The effects were pronounced. In Caov-4 cells, a human ovarian cancer line, and in ID8 cells, a mouse ovarian cancer model, loss of PTK6 markedly suppressed both proliferation and migration. The researchers used a battery of complementary assays to quantify these effects: CCK-8 assays to measure cell viability over time, EdU incorporation to detect cells actively synthesizing DNA, colony formation assays to test the ability of single cells to establish new populations, and wound healing assays to assess collective migration. Across these readouts, PTK6-depleted cells consistently underperformed their normal counterparts, indicating that the kinase supports multiple hallmarks of cancer behavior simultaneously.

The most demanding test came in living animals. When the researchers implanted Caov-4 cells into mice, cells carrying shRNA-mediated PTK6 knockdown showed a significantly impaired ability to form subcutaneous tumors compared with control cells. This in vivo result is critical, because the tumor environment is far more complex than a culture dish, requiring cells to survive immune surveillance, recruit blood supply, and withstand mechanical and metabolic stress. A gene whose loss cripples tumor formation in an animal is a far more credible drug target than one whose effects appear only under laboratory conditions.

Having established that PTK6 matters, the team turned to the therapeutic question: can it be drugged? Their candidate was tilfrinib, a small-molecule kinase inhibitor. Molecular docking analysis, a computational technique that models how a drug fits into the three-dimensional structure of its target protein, demonstrated that tilfrinib forms a stable complex with PTK6, binding within the kinase’s active site in a configuration consistent with potent inhibition. Encouragingly, the computational prediction translated into biological activity. When ovarian cancer cells were treated with tilfrinib, the drug produced a dose-dependent suppression of proliferation, meaning that higher concentrations of the compound produced stronger growth inhibition. Dose responsiveness is an important pharmacological signature, indicating that the drug’s effect is specific and titratable rather than a nonspecific toxic artifact.

The convergence of evidence is what makes the study notable. PTK6 is overexpressed in ovarian tumors; its expression tracks with worse survival across three independent clinical measures; it is concentrated in malignant epithelial cells; removing it genetically impairs proliferation, migration, and tumor formation; and inhibiting it pharmacologically with tilfrinib reproduces the anti-proliferative effect in a dose-dependent manner. Each line of evidence reinforces the others, and together they argue that PTK6 promotes ovarian cancer progression by enhancing tumor cell proliferation and migration, as the authors conclude. The study was approved by the Research Ethics Board of Xiangyang Central Hospital and conducted in compliance with the Declaration of Helsinki, with animal work approved by the relevant ethics committee of Hubei University of Arts and Science.

Clinically, the findings arrive at a moment when ovarian cancer treatment is in need of new molecular approaches. Standard therapy, combining cytoreductive surgery with platinum-based chemotherapy, followed in many cases by PARP inhibitors for patients with homologous recombination deficiencies, has improved outcomes for some, but most patients with advanced disease eventually relapse. A kinase inhibitor targeting PTK6 would represent a distinct mechanism, potentially applicable to the broader population of patients whose tumors overexpress the enzyme. The authors suggest that inhibition of PTK6 by tilfrinib represents a promising therapeutic strategy for ovarian cancer, though they are careful to frame the work as preclinical. The experiments were performed in cell lines and mouse models, and the path from such results to an approved medicine typically involves further validation in additional models, pharmacokinetic and safety profiling, and eventually clinical trials.

Nevertheless, the study adds ovarian cancer to the growing map of PTK6-driven malignancies and provides a concrete chemical starting point for targeting it. By combining multi-omics data mining, single-cell analysis, genetic knockdown, animal tumorigenicity assays, and molecular docking into a single coherent investigation, the researchers have built the kind of multi-pronged case that drug developers look for when deciding whether a target is worth pursuing. If tilfrinib or related compounds can be advanced toward the clinic, patients with PTK6-high ovarian tumors may one day have a targeted option matched to the molecular signature of their disease. For now, the work stands as a rigorous demonstration that a single kinase, long suspected of fueling epithelial cancers, plays a central and druggable role in one of medicine’s most stubborn tumors.

Subject of Research: PTK6 kinase inhibition by tilfrinib as a therapeutic strategy against ovarian cancer cell proliferation and migration

Article Title: PTK6 inhibition by tilfrinib hinders the proliferation and migration of ovarian cancer cells

Article References: PTK6 inhibition by tilfrinib hinders the proliferation and migration of ovarian cancer cells. (n.d.). https://doi.org/10.1186/s13048-026-02254-z

Image Credits: AI Generated

DOI: 10.1186/s13048-026-02254-z

Keywords: ovarian cancer, PTK6, tilfrinib, kinase inhibitor, cell proliferation, cell migration, molecular docking, targeted therapy, single-cell transcriptomics, tumor progression, drug target, gynecologic oncology